In one paragraphArticle in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Jiajun Li *Liver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0009-0008-8760-1365 Ziyu Ren *Liver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0009-0009-1030-8360 Jiamei Yao *Liver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0000-0002-3958-2357 Yingying ZhaoLiver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0009-0009-9166-9378 Ye XuLiver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0009-0009-9407-5276 Hongmei YuLiver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0009-0006-2936-0941 Mimi WangLiver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0000-0002-9727-8943 Fan YaoLiver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0009-0002-8222-6742 Miao LiLiver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0000-0001-7840-7511 Dongmei GaoLiver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0000-0003-3442-5704 Yan ZhaoLiver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0009-0003-2348-452X Binbin LiuLiver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0000-0002-3458-4046 Yinying DongDepartment of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, PR China.ORCID 0009-0000-3345-4170 Rongxin ChenLiver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0000-0001-8508-516X Jiefeng CuiLiver Cancer Institute, Zhongshan Hospital, Fudan University & Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, PR China.ORCID 0000-0001-6996-720X Funding
National Natural Science Foundation of China (NSFC) 82473492
6 · The paper itselfAbstract
Increased matrix stiffness is a biomechanical feature of hepatocellular carcinoma (HCC) that functions as an important promoting factor driving tumor progression. Characterization of the mechanosensors and the underlying downstream mechanisms driving HCC could help identify potential treatment strategies. In this study, we developed a standard procedure for screening and identifying mechanosensors, revealing two HCC mechanosensors, SDC4 and PKD2. These two mechanosensory pathways collaboratively mediated matrix stiffness-promoted DNA damage repair (DDR). Specifically, SDC4 and PKD2 modulated matrix stiffness-increased BANF1 nuclear translocation by increasing protein phosphatase 2A assembly and activity. Subsequently, nuclear BANF1 boosted the formation of the MRE11-RAD50-NBS1 complex and phosphorylation of its downstream effectors to enhance DDR. These findings not only expand the theoretical understanding of matrix stiffness-regulated DDR but also offer a screening/identification approach for mechanosensors in cancer. SIGNIFICANCE: Matrix stiffness enhances DNA repair via dual pathways in hepatocellular carcinoma, suggesting that targeting mechanosensory cross-talk could be a potential strategy to overcome cytotoxic drug resistance.
Indexed as
Carcinoma, HepatocellularDNA DamageDNA RepairLiver NeoplasmsMechanotransduction, CellularCell Cycle ProteinsCell Line, TumorDNA-Binding ProteinsHumansMRE11 Homologue ProteinNuclear ProteinsPhosphorylationProtein Phosphatase 2Cell Cycle ProteinsDNA-Binding ProteinsMRE11 Homologue ProteinMRE11 protein, humanNBN protein, humanNuclear ProteinsProtein Phosphatase 2
Identifiers
PMID42525956
PMCPMC13669727
What OpenQuestion holds
Textmetadata
Read underepoch 390